Drugmaker Novo Nordisk will slash thousands of jobs in a sweeping effort to keep the company competitive in the ...

The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative ...

Novo Nordisk is deeply undervalued despite stellar fundamentals: 18% sales growth, a 29% OP jump, and a rock-solid balance ...

It's no secret that Novo Nordisk ( NVO -1.69%) and Eli Lilly ( LLY 1.57%) are toughing it out in the battle of the weight ...

Denmark's economy remains robust despite job cuts at Novo Nordisk , the finance minister told Reuters on Wednesday, ...

Discover why Novo Nordisk is a top buy with strong GLP-1 drug growth, robust fundamentals, and defensive value.

Novo Nordisk’s popular weight loss drug, Wegovy, is the first and only GLP-1 medication approved to treat metabolic associated steatohepatitis, a serious condition marked by liver scarring. The FDA ...